Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 42
Filtrar
1.
Front Med (Lausanne) ; 9: 1035400, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36530923

RESUMEN

Introduction: Immunity to Human leukocyte antigen (HLA) cannot explain all cases of ABMR, nor the differences observed in the outcome of kidney recipients with circulating DSAs endowed with similar biologic characteristics. Thus, increasing attention has recently been focused on the role of immunity to non-HLA antigenic targets. Methods: We analyzed humoral auto- and alloimmune responses to the non-HLA antigen glutathione S-transferase theta 1 (GSTT1), along with development of de novo (dn)HLA-DSAs, in a cohort of 146 pediatric non-sensitized recipients of first kidney allograft, to analyze its role in ABMR and graft loss. A multiplex bead assay was employed to assess GSTT1 antibodies (Abs). Results: We observed development of GSTT1 Abs in 71 recipients after transplantation, 16 with MFI > 8031 (4th quartile: Q4 group). In univariate analyses, we found an association between Q4-GSTT1Abs and ABMR and graft loss, suggesting a potential role in inducing graft damage, as GSTT1 Abs were identified within ABMR biopsies of patients with graft function deterioration in the absence of concomitant intragraft HLA-DSAs. HLA-DSAs and GSTT1 Abs were independent predictors of graft loss in our cohort. As GSTT1 Ab development preceded or coincided with the appearance of dnHLA-DSAs, we tested and found that a model with the two combined parameters proved more fit to classify patients at risk of graft loss. Discussion: Our observations on the harmful effects of GSTT1Abs, alone or in combination with HLA-DSAs, add to the evidence pointing to a negative role of allo- and auto-non-HLA Abs on kidney graft outcome.

2.
Transpl Immunol ; 65: 101375, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33610675

RESUMEN

While de novo donor-specific HLA antibodies (dnDSAs) have a detrimental impact on kidney graft outcome, the clinical significance of de novo non donor-specific antibodies (dnNDSAs) is more controversial. We retrospectively evaluated for Ab development and characteristics of dnNDSAs serially collected post-transplant sera and, when available, graft biopsy eluates, from 144 non-sensitized, primary pediatric kidney recipients, consecutively transplanted at a single center between 2003 and 2017, using HLA class I and class II single-antigen flow-bead assays (SAB). The results were compared with clinical-pathologic data from HLA antibody negative and HLA dnDSA-positive patients. Forty-five out of 144 patients developed dnNDSAs (31%). Among the dnNDSA-positive patients, 86% displayed one or more class I/II antibodies recognizing antigens included in the CREG/shared epitope groups that also comprise the mismatched donor HLA antigens. Despite potential pathogenicity, as suggested by their occasional presence within the graft, dnNDSAs displayed significantly lower MFI, and limited complement binding and graft homing properties, when compared with dnDSAs. In parallel, the graft survival probability was significantly lower in patients with dnDSA than in those with dnNDSA or without HLA antibodies (p < 0.005). Indeed, the dnNDSA-positive patients remaining dnDSA-negative throughout the posttransplant period did not develop clinical antibody mediated rejection and graft loss, and maintained good graft function at a median follow-up of 9 years. The biological characteristics of dnNDSAs may account for the low graft damaging capability when compared to dnDSAs.


Asunto(s)
Trasplante de Riñón , Niño , Rechazo de Injerto , Supervivencia de Injerto , Antígenos HLA , Humanos , Isoanticuerpos , Estudios Retrospectivos , Donantes de Tejidos
3.
Transpl Int ; 32(1): 38-48, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30076765

RESUMEN

Current research is focusing on identifying bioclinical parameters for risk stratification of renal allograft loss, largely due to antibody-mediated rejection (AMR). We retrospectively investigated graft outcome predictors in 24 unsensitized pediatric kidney recipients developing HLA de novo donor-specific antibodies (dnDSAs), and treated for late AMR with plasmapheresis + low-dose IVIG + Rituximab or high-dose IVIG + Rituximab. Renal function and DSA properties were assessed before and longitudinally post treatment. The estimated GFR (eGFR) decline after treatment was dependent on a negative % eGFR variation in the year preceding treatment (P = 0.021) but not on eGFR at treatment (P = 0.74). At a median follow-up of 36 months from AMR diagnosis, 10 patients lost their graft. Altered eGFR (P < 0.001) and presence of C3d-binding DSAs (P = 0.005) at treatment, and failure to remove DSAs (P = 0.01) were negatively associated with graft survival in the univariable analysis. Given the relevance of DSA removal for therapeutic success, we analyzed antibody properties dictating resistance to anti-humoral treatment. In the multivariable analysis, C3d-binding ability (P < 0.05), but not C1q-binding, and high mean fluorescence intensity (P < 0.05) were independent factors characterizing DSAs scarcely susceptible to removal. The poor prognosis of late AMR is related to deterioration of graft function prior to treatment and failure to remove C3d binding and/or high-MFI DSAs.


Asunto(s)
Rechazo de Injerto/inmunología , Supervivencia de Injerto/inmunología , Antígenos HLA/inmunología , Isoanticuerpos/inmunología , Trasplante de Riñón , Riñón/inmunología , Adolescente , Anticuerpos , Biopsia , Niño , Femenino , Estudios de Seguimiento , Humanos , Masculino , Análisis Multivariante , Pronóstico , Estudios Retrospectivos , Riesgo , Rituximab/administración & dosificación , Donantes de Tejidos
4.
J Immunol Res ; 2017: 1747030, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28367453

RESUMEN

De novo posttransplant donor-specific HLA-antibody (dnDSA) detection is now recognized as a tool to identify patients at risk for antibody-mediated rejection (AMR) and graft loss. It is still unclear whether the time interval from transplant to DSA occurrence influences graft damage. Utilizing sera collected longitudinally, we evaluated 114 consecutive primary pediatric kidney recipients grafted between 2002 and 2013 for dnDSA occurrence by Luminex platform. dnDSAs occurred in 39 patients at a median time of 24.6 months. In 15 patients, dnDSAs developed within 1 year (early-onset group), while the other 24 seroconverted after the first posttransplant year (late-onset group). The two groups were comparable when considering patient- and transplant-related factors, as well as DSA biological properties, including C1q and C3d complement-binding ability. Only recipient age at transplant significantly differed in the two cohorts, with younger patients showing earlier dnDSA development. Late AMR was diagnosed in 47% of the early group and in 58% of the late group. Graft loss occurred in 3/15 (20%) and 4/24 (17%) patients in early- and late-onset groups, respectively (p = ns). In our pediatric kidney recipients, dnDSAs predict AMR and graft loss irrespective of the time elapsed between transplantation and antibody occurrence.


Asunto(s)
Rechazo de Injerto/inmunología , Antígenos HLA/inmunología , Isoanticuerpos/sangre , Isoanticuerpos/inmunología , Trasplante de Riñón/efectos adversos , Adolescente , Factores de Edad , Niño , Complemento C1q/inmunología , Complemento C3d/inmunología , Femenino , Humanos , Estudios Longitudinales , Masculino , Estudios Retrospectivos , Factores de Riesgo , Donantes de Tejidos
5.
Nephrol Dial Transplant ; 32(1): 191-195, 2017 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-27742824

RESUMEN

Background: High levels of preformed anti-HLA antibodies dramatically diminish renal transplant outcomes. Most desensitization programmes guarantee good intermediate outcomes but quite disappointing long-term prognosis. The search for a fully compatible kidney increases time on the waiting list. Methods: In February 2011, a nationwide hyperimmune programme (NHP) was begun in Italy: all available kidneys are primarily proposed to highly sensitized patients with a panel reactive antibody above 80%. In this manuscript, we evaluate the outcome of paediatric patients transplanted with this approach. Results: Twenty-one patients were transplanted. Complete data are available for 20 patients. Mean age at transplantation was 14.5 years [standard deviation (SD) ± 5.5)]. Mean time on the waiting list was 29.3 months (SD ± 27.5). Median follow-up was 29.2 months (range: 11.2-59.3). The average number of HLA mismatches in these patients was 2.3 versus 3.7 in 48 standard patients transplanted in the same period (P < 0.001). Only one graft was lost. Two cases of humoral rejection occurred and were successfully treated. No cellular rejection was reported. Median creatinine clearance was 84, 88, 77 and 77 mL/min/1.73 m 2 respectively 1, 6, 12 and 24 months after transplant. Conclusions: Transplantation of sensitized patients avoiding prohibited antigens is feasible, at least in a selected cohort of patients. In order to be able to further improve this approach, which in our opinion is very successful, it would be necessary to expand the donor pool, possibly increasing the number of countries participating in the programme. In this series, time on the waiting list did not increase significantly. This allocation policy should ideally lead to an outcome comparable to that expected in standard patients, which is particularly desirable in young patients who have the longest life expectancy. Since long-term results of desensitization programmes are not (yet) convincing, we suggest that these programmes should be reserved for selected cases where compatible organs cannot be found within a reasonable time span.


Asunto(s)
Desensibilización Inmunológica/métodos , Supervivencia de Injerto/inmunología , Antígenos HLA/inmunología , Fallo Renal Crónico/inmunología , Trasplante de Riñón , Adolescente , Adulto , Niño , Preescolar , Femenino , Antígenos HLA/sangre , Prueba de Histocompatibilidad , Humanos , Isoanticuerpos/sangre , Masculino , Adulto Joven
8.
Transplantation ; 99(1): 243-9, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25033258

RESUMEN

BACKGROUND: Development of de novo donor-specific antibodies (dnDSA) is associated with late or chronic antibody-mediated rejection (CAMR) and poor graft outcome in low-risk kidney transplant recipients. High-level soluble B-cell activating factor (sBAFF) was observed in kidney recipients at higher risk of developing dnDSA. METHODS: We longitudinally analyzed sBAFF levels in 81 consecutive primary pediatric kidney recipients monitored for de novo human leukocyte antigen (HLA) antibody (Ab) occurrence to gain insight into the events conditioning B-cell activation posttransplant and to analyze the usefulness of paired DSA-sBAFF monitoring in this clinical setting. RESULTS: At a median follow-up of 65 months, 23 patients (28%) developed dnDSA, with 13 of 23 developing CAMR. Irrespective of HLA Ab status, sBAFF levels progressively increased in all patients in the first posttransplant year, thereafter reaching a plateau. sBAFF levels were influenced by the degree of HLA class I antigen match and donor age. Despite higher levels of sBAFF in HLA Ab-positive patients (median and 95% confidence interval sBAFF in DSA+non-DSA patients: 568, 534-608 pg/mL vs. 502, 422-548 pg/mL in Ab-negative patients; P<0.05), we found that sBAFF monitoring could not predict DSA development by a time to event longitudinal analysis. Moreover, sBAFF kinetics up to CAMR onset could not anticipate CAMR development in the DSA cohort. CONCLUSION: Our findings provide evidence of early posttransplant B-cell activation even in unsensitized recipients of first kidney allograft. The significance of this activation, likely induced by exposition to the allograft, is yet unclear.


Asunto(s)
Factor Activador de Células B/sangre , Trasplante de Riñón , Enfermedad Aguda , Adolescente , Adulto , Factores de Edad , Biomarcadores/sangre , Niño , Preescolar , Femenino , Rechazo de Injerto/sangre , Rechazo de Injerto/inmunología , Antígenos HLA/inmunología , Humanos , Isoanticuerpos/sangre , Cinética , Estudios Longitudinales , Masculino , Monitorización Inmunológica/métodos , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento , Regulación hacia Arriba , Adulto Joven
9.
Pediatr Transplant ; 18(4): 350-6, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24802342

RESUMEN

The three yr results of a multicenter trial in de novo pediatric KT treated with a proliferative signal inhibitor and low dose CNI are presented. Thirty-seven children (9.1 ± 5 yr old) received basiliximab, cyclosporine A (CyA C2:1400 ng/mL), (MMF C0:1.5-3 µg/mL), and prednisone. Three wk later everolimus was started (C0:5-10 ng/mL), CyA was reduced (C2:600 ng/mL after 90 days 300 ng/mL), and MMF discontinued. During the three-yr period patient and graft survivals were 96%. One patient died for causes unrelated to the immunosuppression. Cumulative acute rejection rate including protocol and indication biopsies was 21.9%. None of the patients had signs of chronic humoral rejection. Incidence of dnDSA was 5%, 11%, and 22% at one, two, and three yr post-transplant, respectively. Mean glomerular filtration rate measured at one yr and three yr post-transplant was 105.5 ± 31 and 110.7 ± 27 mL/min/1.73 m(2), respectively. A growth velocity of 7.7 ± 6.7 cm/yr was achieved with positive catch-up growth. No malignancy or post-transplant lymphoproliferative diseases were diagnosed. In conclusion, the treatment based on basiliximab induction, everolimus, low-dose cyclosporine, and low-dose prednisone leads to good long-term efficacy in de novo pediatric KT recipients.


Asunto(s)
Ciclosporina/uso terapéutico , Rechazo de Injerto/prevención & control , Inmunosupresores/uso terapéutico , Trasplante de Riñón , Sirolimus/análogos & derivados , Adolescente , Anticuerpos Monoclonales/uso terapéutico , Basiliximab , Niño , Preescolar , Esquema de Medicación , Quimioterapia Combinada , Everolimus , Femenino , Rechazo de Injerto/diagnóstico , Rechazo de Injerto/epidemiología , Supervivencia de Injerto , Humanos , Estimación de Kaplan-Meier , Trasplante de Riñón/mortalidad , Masculino , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapéutico , Prednisona/uso terapéutico , Estudios Prospectivos , Proteínas Recombinantes de Fusión/uso terapéutico , Sirolimus/uso terapéutico , Resultado del Tratamiento
10.
Transpl Int ; 27(7): 667-73, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24629017

RESUMEN

Data on the different HLA-antibody (Ab) categories in pediatric kidney recipients developing de novo donor-specific Abs (DSA) after transplantation are scarce. We retrospectively evaluated 82 consecutive nonsensitized pediatric recipients of a first kidney graft for de novo HLA Ab occurrence and antigen specificity. At a median follow-up of 6 years, 29% of patients developed de novo DSA, while 45% had de novo non-DSA. DSA appeared at 25-month median time post-transplant and were mostly directed toward HLA-DQ antigens. Considering each HLA antigen, the estimated rate of DQ DSA (7.55 per 100 person-years) was much higher than the rates observed for non-DQ DSA. The HLA-DQ Ab recognized determinants of the DQß chain in 70% of cases, α chain in 25% of cases, and both chains in one patient. Non-DSA peaked earlier than DSA, and were largely directed against HLA class I specificities that belonged to HLA-A- and HLA-B-related cross-reacting epitope groups (CREG) in 56% of cases. Our results indicate a need for evaluating HLA-DQ compatibilities in kidney allocation, in order to minimize post-transplant development of de novo DSA, known to be responsible for antibody-mediated rejection and graft loss.


Asunto(s)
Antígenos HLA-DQ/inmunología , Trasplante de Riñón , Donantes de Tejidos , Adolescente , Adulto , Niño , Preescolar , Femenino , Rechazo de Injerto/inmunología , Supervivencia de Injerto/inmunología , Humanos , Masculino , Estudios Retrospectivos
11.
Clin Dev Immunol ; 2013: 256923, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24000288

RESUMEN

Polyomavirus BK-associated nephropathy (PyVAN) is the main infectious cause of allograft damage after kidney transplantation. A number of studies revealed an association between the presence of BKV-specific cellular immunity and BK viral clearance, with patients failing to recover specific T cells progressing to PyVAN. Evolution to allograft dysfunction can be prevented by restoration of BKV-specific immunity through a stepwise reduction of maintenance immunosuppressive drugs. Prospective monitoring of BK viral load and specific immunity, together with B-cell alloimmune surveillance, may allow a targeted modification/reduction of immunosuppression, with the aim of obtaining viral clearance while preventing graft injury due to deposition of de novo donor-specific HLA antibodies and late/chronic antibody-mediated allograft injury. Innovative, immune-based therapies may further contribute to BKV infection prevention and control.


Asunto(s)
Virus BK/inmunología , Infecciones por Polyomavirus/inmunología , Animales , Citotoxicidad Celular Dependiente de Anticuerpos , Rechazo de Injerto/inmunología , Humanos , Vigilancia Inmunológica , Inmunoterapia , Enfermedades Renales/diagnóstico , Enfermedades Renales/inmunología , Enfermedades Renales/prevención & control , Enfermedades Renales/terapia , Enfermedades Renales/virología , Trasplante de Riñón/efectos adversos , Infecciones por Polyomavirus/diagnóstico , Infecciones por Polyomavirus/prevención & control , Infecciones por Polyomavirus/terapia , Trasplante Homólogo
12.
Pediatr Transplant ; 17(7): E168-73, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23992468

RESUMEN

CHL type is the least common major form of EBV-related PTLD but rarely occurs in pediatric recipients; development of CHL subsequent to other PTLD subtypes in the same transplant recipient is even more unusual. Because of its rarity, indications on the best treatment strategy are limited. Patients have been mostly treated with standard HL chemotherapy/radiotherapy, and prognosis seems more favorable than other monomorphic PTLDs. Herein, we describe a pediatric case of EBV-associated, stage IV-B, CHL arising in a heart allograft recipient eight yr after diagnosis of B-cell polymorphic PTLD. The patient was successfully treated with adjusted-dose HL chemotherapy and autologous EBV-specific CTL, without discontinuation of maintenance immunosuppression. At two yr from therapy completion, the patient is in CR with stable organ function. With this strategy, it may be possible to reproduce the good prognostic data reported for CHL-type PTLD, with decreased risk of organ toxicity or rejection.


Asunto(s)
Cardiomiopatía Dilatada/terapia , Infecciones por Virus de Epstein-Barr/complicaciones , Trasplante de Corazón , Enfermedad de Hodgkin/terapia , Trastornos Linfoproliferativos/terapia , Linfocitos T Citotóxicos/citología , Médula Ósea/patología , Quimioterapia , Infecciones por Virus de Epstein-Barr/inmunología , Herpesvirus Humano 4 , Enfermedad de Hodgkin/virología , Humanos , Inmunofenotipificación , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Lactante , Trastornos Linfoproliferativos/virología , Masculino , Factores de Tiempo , Resultado del Tratamiento
13.
G Ital Nefrol ; 29 Suppl 56: S99-108, 2012.
Artículo en Italiano | MEDLINE | ID: mdl-23059947

RESUMEN

Advances in immunosuppression have lowered the acute rejection rates in kidney transplant recipients but have impacted negatively on the viral infection rates. Polyomavirus-associated interstitial nephropathy (PyVA N) affects up to 10% of kidney transplant recipients and can progress to irreversible allograft failure in up to 45% of affected cases. Nowadays, thanks to increased awareness of PyVA N and improved diagnostic techniques, the rate of graft loss has decreased, most markedly in centers with active screening and intervention programs. The diagnosis of PyVA N is made by allograft histology. However, systematic screening by quantitative molecular-genetic techniques allows intervention in the early stages of the disease, before the occurrence of irreversible parenchymal changes. So far, the only proven measure affecting PyVA N progression and outcome is the reduction of immunosuppression. Other therapeutic approaches including cidofovir, leflunomide, fluoroquinolones and intravenous immunoglobulins have been explored, but there is no clinical evidence supporting their efficacy. It has been largely demonstrated that BKV-specific T-cell immunity plays a pivotal role in controlling viral replication and disease progression. For this reason viral-specific T-cell immunity can help in monitoring PyVA N. Protocols of adoptive T-cell transfer based on infusion of BKV-specific T cells are the object of many studies and should be considered an innovative treatment approach for PyVA N.


Asunto(s)
Virus BK , Trasplante de Riñón , Infecciones por Polyomavirus , Complicaciones Posoperatorias/virología , Infecciones Tumorales por Virus , Virus BK/fisiología , Humanos , Infecciones por Polyomavirus/diagnóstico , Infecciones por Polyomavirus/terapia , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/terapia , Factores de Riesgo , Infecciones Tumorales por Virus/diagnóstico , Infecciones Tumorales por Virus/terapia , Replicación Viral
15.
Pediatr Nephrol ; 27(5): 705-17, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-21359619

RESUMEN

Viral infections remain a significant cause of morbidity and mortality following renal transplantation. The pediatric cohort is at high risk of developing virus-related complications due to immunological naiveté and the increased alloreactivity risk that requires maintaining a heavily immunosuppressive environment. Although cytomegalovirus is the most common opportunistic pathogen seen in transplant recipients, numerous other viruses may affect clinical outcome. Recent technological advances and novel antiviral therapy have allowed implementation of viral and immunological monitoring protocols and adoption of prophylactic or preemptive treatment approaches in high-risk groups. These strategies have led to improved viral infection management in the immunocompromised host, with significant impact on outcome. We review the major viral infections seen following kidney transplantation and discuss strategies for preventing and managing these pathogens.


Asunto(s)
Trasplante de Riñón/fisiología , Virosis/terapia , Virus BK , Niño , Infecciones por Citomegalovirus/terapia , Infecciones por Citomegalovirus/virología , Manejo de la Enfermedad , Infecciones por Virus de Epstein-Barr/terapia , Infecciones por Virus de Epstein-Barr/virología , Herpesvirus Humano 4 , Humanos , Monitoreo Fisiológico , Infecciones por Polyomavirus/terapia , Infecciones por Polyomavirus/virología , Virosis/diagnóstico , Virosis/inmunología , Virosis/virología
16.
G Ital Nefrol ; 28(1): 15-25, 2011.
Artículo en Italiano | MEDLINE | ID: mdl-21341241

RESUMEN

A living-donor kidney transplant offers a child at the terminal stages of renal disease better functional recovery and quality of life than an organ from a deceased donor. Before starting the procedure for a living-donor transplant, however, it is necessary to establish if it is really safe. There are diseases, such as focal segmental glomerulosclerosis, atypical HUS and membranoproliferative glomerulonephritis with dense deposits, for which living donation is not recommended given the high incidence of recurrence of the disease but also the frequent loss of the graft. Regarding the selection of the donor, an increased risk of acute rejection has been reported for donors older than 60-65 years and a worsening of the renal outcome if the donor's weight is equal to or less than the recipient's. Finally, it is necessary to take into consideration that complications may arise in the donor both in the perioperative period and in the long term. In conclusion, kidney transplant from a living donor is a natural choice within the pediatric setting. The parents, usually young and highly motivated to donate, are the ideal donors. However, although the risks associated with donation are minimal, they are not totally absent, and consequently it is mandatory to follow standardized procedures according to the guidelines issued by the Centro Nazionale Trapianti.


Asunto(s)
Trasplante de Riñón , Donadores Vivos , Niño , Humanos
17.
Transplantation ; 88(3): 417-20, 2009 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-19667947

RESUMEN

BACKGROUND: Focal and segmental glomerulosclerosis (FSGS) accounts for more than 10% of all cases of renal diseases leading to renal failure in children. After renal transplantation, 20% to 40% of FSGS relapse, frequently leading to renal loss.Plasmapheresis is considered the first option to treat relapses by several authors but is often ineffective. The anti-CD20 monoclonal antibody rituximab has been proposed as a possible treatment. METHODS: We reviewed the effect of rituximab in seven children or young adults with pretransplant FSGS and relapse of proteinuria after transplantation who did not respond to intensive plasmapheresis. RESULTS: After treatment, urine protein disappeared in three patients, was reduced by 70% in one patient and by 50% in one patient. No response was observed in one patient who had a quick deterioration of renal function and reached end-stage renal failure after 3 months. One additional patient developed a severe reaction a few minutes after the start of the first rituximab infusion. CONCLUSION: Rituximab is a possible option to treat some resistant cases of FSGS with relapsing proteinuria after transplantation. It is important that therapy is started early after evidence of failure of plasmapheresis, before sclerosis develops in the glomeruli. The response to treatment can occur after several months. During the follow-up period, CD19 cells should be monitored carefully, and additional rituximab infusions considered to maintain B-cell depletion.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Glomeruloesclerosis Focal y Segmentaria/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Trasplante de Riñón/efectos adversos , Adolescente , Adulto , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales de Origen Murino , Antígenos CD19/análisis , Linfocitos B/efectos de los fármacos , Linfocitos B/inmunología , Niño , Preescolar , Estudios de Cohortes , Progresión de la Enfermedad , Glomeruloesclerosis Focal y Segmentaria/inmunología , Glomeruloesclerosis Focal y Segmentaria/cirugía , Humanos , Inmunosupresores/efectos adversos , Fallo Renal Crónico/inmunología , Fallo Renal Crónico/prevención & control , Plasmaféresis , Proteinuria/tratamiento farmacológico , Proteinuria/inmunología , Recurrencia , Rituximab , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
18.
J Clin Microbiol ; 47(8): 2577-85, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19474265

RESUMEN

BK virus (BKV)-specific immunity is critical for polyomavirus-associated nephropathy, but antibody responses are incompletely defined. We compared the hemagglutination inhibition assay (HIA) with immunoglobulin G enzyme immunoassays (EIA) to BKV proteins expressed in baculovirus-infected insect cells. N-terminal, internal, and C-terminal domains of the BKV large T antigen (BKLT) were fused to glutathione S-transferase (GST), yielding GST-BKLTD1, GST-BKLTD2, and GST-BKLTD3, respectively. The BKV capsid VP1 was expressed as a GST fusion (BKVP1) or as a native VP1 assembled into viruslike particles (BKVLP). We tested 422 sera from 28 healthy donors (HD), 99 dialysis patients (DP; median age, 15 years; range, 3 to 32 years), and 46 age-matched kidney transplant patients (KTP; median age, 15 years; range, 2 to 33 years). In HD, HIA and BKVLP EIA both yielded a 91.7% seroreactivity, whereas all other EIA responses were lower (BKVP1, 83.3%; BKLTD1, 25%; BKLTD2, 29%; BKLTD3, 40%). HIA titers significantly correlated with EIA levels for BKVLP, BKVP1, and BKLTD1 but not for BKLTD2 or BKLTD3, which were barely above the cutoff. In DP, the seroreactivities of HIA, BKVLP, and BKLTD1 were lower than that in HD (63.6%, 86.9%, and 10.1%, respectively) and they had lower titers (P < 0.001). In KTP, seropositivities for BKVLP, BKVP1, and BKLTD1 were 78%, 50%, and 17%, respectively, but anti-BKVLP levels increased significantly in KTP with viruria and viremia, whereas anti-BKLTD1 levels increased after clearing sustained BKV viremia. In conclusion, anti-BKVLP is equivalent to HIA in HD but is more sensitive to determine the BKV serostatus in DP and KTP. In KTP, anti-BKVLP responds to recent BKV viruria and viremia, whereas anti-BKLTD1 may indicate emerging BKV-specific immune control.


Asunto(s)
Anticuerpos Antivirales/sangre , Antígenos Transformadores de Poliomavirus , Virus BK/inmunología , Proteínas de la Cápside , Ensayo de Inmunoadsorción Enzimática/métodos , Pruebas de Inhibición de Hemaglutinación/métodos , Infecciones por Polyomavirus/inmunología , Adolescente , Adulto , Animales , Antígenos Transformadores de Poliomavirus/genética , Baculoviridae/genética , Sangre/virología , Proteínas de la Cápside/genética , Niño , Preescolar , Vectores Genéticos , Humanos , Trasplante de Riñón , Infecciones por Polyomavirus/virología , Proteínas Recombinantes/genética , Orina/virología , Adulto Joven
19.
Nephrol Dial Transplant ; 24(9): 2931-7, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19349296

RESUMEN

BACKGROUND: The main cause of reduced long-term graft survival is chronic allograft injury. Cardiovascular risk factors such as hyperhomocysteinaemia, accumulation of asymmetric dimethylarginine, increased oxidative stress and decreased production of nitric oxide seem to play an important role. Functional polymorphisms of the endothelial isoform of nitric oxide synthase (NOS) gene cause an alteration in nitric oxide production. Nitric oxide levels, and thus oxidative stress, are also influenced by hyperhomocysteinaemia. METHODS: We carried out a genetic analysis of endothelial nitric oxide synthase (eNOS) 894G>T, methionine synthase (MTR) 2756A>G and methylenetetrahydrofolate reductase (MTHFR) 677C>T/1298A>C in 268 renal allograft recipient/donor (D/R) matches, with respect to long-term graft survival. RESULTS: While MTHFR 677C>T/1298A>G and MTR 2756A>G polymorphism distribution in both recipients (R) and donors (D) showed no significant difference between matches with loss of graft function and those with long-term graft survival, the frequency of the eNOS 894TT genotype of donors was significantly increased (P = 0.040) in matches with better graft survival. The multivariate analysis identified the eNOS 894 genotype and clinically acute rejection episodes as independent risk factors for graft loss (P = 0.0406 and P = 0.0093, respectively). CONCLUSIONS: The association between eNOS 894G>T polymorphism of donors and graft survival seems to suggest a role for this gene in chronic allograft injury; however, further studies are needed to confirm this hypothesis.


Asunto(s)
5-Metiltetrahidrofolato-Homocisteína S-Metiltransferasa/genética , Supervivencia de Injerto/genética , Supervivencia de Injerto/fisiología , Trasplante de Riñón/fisiología , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Óxido Nítrico Sintasa de Tipo III/genética , Polimorfismo de Nucleótido Simple , Adolescente , Adulto , Niño , Preescolar , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Lactante , Recién Nacido , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo , Adulto Joven
20.
Clin Transplant ; 23(2): 264-70, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19191807

RESUMEN

This longitudinal study assessed the influence of post-transplant clinical and therapeutic variables in 50 kidney transplant recipients aged 2-19 yr receiving a triple immunosuppressive regimen consisting of cyclosporine microemulsion (CsA), steroids and MMF (300-400 mg/m(2) body surface area twice daily), the full pharmacokinetic profile (10 points) of which was investigated on post-transplant days 6, 30, 180 and 360. Total plasma MPA was measured by Enzyme Multiplied Immunoassay Technique. CsA therapeutic drug monitoring (TDM) was performed via C2 blood monitoring, while MPA TDM via C0. MPA Cmax, tmax, AUC0-12 and AUC0-4 pharmacokinetic profile changed significantly during the first post-transplant year. C0 was a poor predictor of the total MPA exposure [as measured by the area under the concentration-time curve AUC)], while a truncated AUC was a good surrogate of the 12-h profile (r = 0.91; p < 0.001) Graft function and cyclosporine therapy influenced MPA pharmacokinetics, as shown by the univariate and multivariate analyses. We conclude that because after transplantation MPA exposure varied over time, a strict TDM is advisable in the pediatric population.


Asunto(s)
Antibióticos Antineoplásicos/farmacocinética , Inmunosupresores/farmacocinética , Trasplante de Riñón , Ácido Micofenólico/farmacocinética , Adolescente , Corticoesteroides/farmacocinética , Adulto , Área Bajo la Curva , Niño , Preescolar , Ciclosporina/farmacocinética , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Estudios Longitudinales , Masculino , Ácido Micofenólico/análogos & derivados , Periodo Posoperatorio , Distribución Tisular , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...